IL17A and pulmonary fibrosis: HFD administration leads to pulmonary fibrosis by causing insulin resistance, a chronic inflammatory response, pro-oxidative/antioxidative imbalance, and increased levels of profibrogenic factors, including TGF-β, IL-17, NE, and MMP-9.